Cadrenal Therapeutics Valuation

Is CVKD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CVKD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CVKD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CVKD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CVKD?

Key metric: As CVKD is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CVKD. This is calculated by dividing CVKD's market cap by their current book value.
What is CVKD's PB Ratio?
PB Ratio	7.1x
Book	US$3.41m
Market Cap	US$26.72m

CVKD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-2.8x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does CVKD's PB Ratio compare to its peers?

The above table shows the PB ratio for CVKD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	10.2x
GSTK Growth Stalk Holdings	27.6x	n/a	US$25.1m
ATHA Athira Pharma	0.4x	25.3%	US$24.8m
PYPD PolyPid	11.4x	-1.7%	US$24.1m
LPCN Lipocine	1.4x	4.5%	US$27.5m
CVKD Cadrenal Therapeutics	7.1x	-21.5%	US$26.7m

Price-To-Book vs Peers: CVKD is good value based on its Price-To-Book Ratio (7.1x) compared to the peer average (10.2x).

Price to Book Ratio vs Industry

How does CVKD's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 Companies	Price / Book	Estimated Growth	Market Cap
SHWZ Medicine Man Technologies	0.09x	n/a	US$8.82m
TNFA TNF Pharmaceuticals	0.2x	n/a	US$3.69m
UPC Universe Pharmaceuticals	0.1x	n/a	US$3.04m
CYTO Altamira Therapeutics	0.2x	-5.9%	US$1.44m

23 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: CVKD is expensive based on its Price-To-Book Ratio (7.1x) compared to the US Pharmaceuticals industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is CVKD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CVKD PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	7.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CVKD's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CVKD forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	US$13.56	US$35.67 +163.0%	18.6%	US$45.00	US$30.00	n/a	3
Nov ’25	US$17.60	US$45.00 +155.7%	27.2%	US$60.00	US$30.00	n/a	3
Oct ’25	US$12.89	US$45.00 +249.1%	27.2%	US$60.00	US$30.00	n/a	3
Sep ’25	US$7.62	US$52.50 +589.4%	14.3%	US$60.00	US$45.00	n/a	2
Aug ’25	US$6.43	US$52.50 +715.9%	14.3%	US$60.00	US$45.00	n/a	2
Jul ’25	US$6.97	US$52.50 +653.3%	14.3%	US$60.00	US$45.00	n/a	2
Jun ’25	US$7.07	US$52.50 +642.6%	14.3%	US$60.00	US$45.00	n/a	2
May ’25	US$6.82	US$52.50 +670.1%	14.3%	US$60.00	US$45.00	n/a	2
Apr ’25	US$9.28	US$52.50 +465.4%	14.3%	US$60.00	US$45.00	n/a	2
Mar ’25	US$10.39	US$52.50 +405.5%	14.3%	US$60.00	US$45.00	n/a	2
Feb ’25	US$21.15	US$52.50 +148.2%	14.3%	US$60.00	US$45.00	n/a	2
Jan ’25	US$11.10	US$52.50 +373.0%	14.3%	US$60.00	US$45.00	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

6.8%

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

6.1%

14.8%